| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Schizophrenia | |||||
| 2 | More general conditions related to this trial | ||||
| Mental Disorders | |||||
| Schizophrenia and Disorders with Psychotic Features | |||||
| 3 | Interventions listed in this trial | ||||
| D-cycloserine | |||||
| Glycine | |||||
| Clozapine | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Cycloserine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Anti-Infective Agents, Urinary | |||||
| Antibiotics, Antitubercular | |||||
| Antimetabolites | |||||
| Antitubercular Agents | |||||
| Glycine Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Renal Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||
|
